ArticleFrontiers in molecular biosciences2026
Screening of potential oxidative stress-related biomarkers and therapeutic drugs in rheumatoid arthritis based on integrative bioinformatics, machine learning, and molecular dynamics simulations.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanobiosensors for Rheumatoid Arthritis Biomarkers: Advances and Clinical Translational Potential.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatoid arthritis (RA) is a prevalent autoimmune condition. Increasing evidence reveals that oxidative stress exerts an important effect in the pathogenesis of RA. This research aimed to systematically screen oxidative stress-related biomarkers for RA and further examine promising therapeutic drugs for RA. Methods: This research first obtained transcriptome data of RA from the GEO database and identified differentially expressed oxidative stress-related genes (DEOSGs). Subsequently, core biomarkers were identified by integrating weighted gene co-expression network analysis with three machine learning algorithms. Their diagnostic performance was assessed utilizing receiver operating characteristic curves, and a clinical predictive nomogram was established. Functional enrichment analysis was implemented to systematically elucidate the biological processes involving DEOSGs in RA, and immune infiltration analysis was conducted concurrently. Furthermore, a potential therapeutic small-molecule compound was screened leveraging the CMap database and validated through molecular docking and molecular dynamics simulation. Finally, the expression levels of the core genes were quantified and analyzed utilizing quantitative real-time polymerase chain reaction and Western blot in a primary human RA synovial fibroblast model. Results: Totally, 281 DEOSGs were identified. These genes were significantly enriched in pathways including the MAPK, AMPK, TNF, and Toll-like receptor signaling pathways. Based on the machine learning algorithms, three core genes were ultimately determined. The diagnostic model established on the basis of these genes demonstrated good diagnostic efficacy. Immune infiltration analysis revealed significant differences in the distribution of immune cell subsets between RA patient samples and normal control samples. Molecular docking and molecular dynamics simulation indicated that narciclasine exhibited good binding affinity with the target protein, and the stability of the binding complex was acceptable. Furthermore, experimental results from the Conclusion: This research preliminarily suggests that CXCL10, EDNRB, and MMP13 may serve as potential oxidative stress-related biomarkers for RA. Simultaneously, it predicts that narciclasine may be a promising candidate drug for RA treatment. These findings offer new insights into the pathogenesis, targeted intervention, and treatment development for RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.